About US
Contact us
-
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatmentJanssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA®(ibrutinib) to the U.S. Food and Drug Administration2014/10/27
-
Roche to invest $3bn to develop Basel site in SwitzerlandRoche is set to invest more than CHF3bn ($3.14bn) to develop a new research and development centre, upgrade infrastructure and renovate the existing office building at its Basel site in Switzerland.2014/10/27
-
FDA accepts Merck and Sanofi’s BLA to review paediatric hexavalent vaccineMerck and Sanofi Pasteur have received approval for review from US Food and Drug Administration (FDA) for investigational paediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB. The FDA accepted the biolo2014/10/24
-
Johnson & Johnson invests $200m to accelerate Ebola vaccine programmeUS-based Johnson & Johnson (J&J) have announced an investment of more than $200m, in a bid to speed up the Ebola vaccine programme at its Janssen Pharmaceutical companies. J&J collaborate2014/10/24
-
FDA accepts Eisai’s sNDA to review antiepileptic drug FycompaJapan-based Eisai has obtained approval for review from US Food and Drug Administration (FDA) for its antiepileptic drug Fycompa (perampanel). The FDA accepted Eisai's supplemental new drug applicati2014/10/23
-
Sanofi Pasteur and Immune Design to develop vaccine for herpes simplex virusVaccines division Sanofi Pasteur has partnered with clinical-stage immunotherapy company Immune Design to develop herpes simplex virus (HSV) immune therapy. As part of the deal, both companies will d2014/10/22
-
AstraZeneca and University of Cambridge partner for research on neurodegenerative diseasesAstraZeneca and subsidiary MedImmune have entered into four new collaborations with the University of Cambridge, expanding on their existing partnership. As part of the three year collaboration, both2014/10/22
-
UPDATED: FDA panel say Pfizer's Chantix should continue to wear a 'black box' labelPfizer's ($PFE) controversial smoking-cessation drugChantixwill continue to be stuck with a black-box warning label at least until late next year, assuming the U.S. Food and Drug Administration follow2014/10/21
-
Ranbaxy to pay $40m to settle overcharging Texas Medicaid programme litigationIndia-based drug maker Ranbaxy Laboratories has agreed to pay $39.75m to settle litigation about its participation in Texas Medicaid, a US health care programme for people with low incomes. The compa2014/10/21
-
Genentech's IPF-treating drug Esbriet receives FDA approvalRoche Group subsidiary Genentech has received approval from US Food and Drug Administration (FDA) for Esbriet (pirfenidone) drug to treat patients with idiopathic pulmonary fibrosis (IPF). Esbriet is2014/10/20